| Characteristics . | Total population (n = 32) . |
|---|---|
| Age, years, median (IQR) | 45 (41–50) |
| Male sex (%) | 57.6 |
| Subtype B (%) | 19.4 |
| CRF02_AG (%) | 53.1 |
| CD4 cell count at VF, cells/mm3, median (IQR) | 243 (103–390) |
| Nadir CD4 cell count, cells/mm3, median (IQR) | 220 (99–319) |
| Plasma HIV viral load at D0, log10 copies/mL, median (IQR) | 5.3 (5–5.5) |
| Plasma HIV viral load at VF, log10 copies/mL, median (IQR) | 2.2 (2–2.7) |
| Time to treatment failure, days, median (IQR) | 495 (366–735) |
| Treatments, number of patients | |
| 2 NRTIs+PI/r | 31 |
| tenofovir/emtricitabine+PI/r | 27 |
| 1 INSTI+PI/r | 1 |
| Protease inhibitors, number of patients | |
| darunavir | 25 (20 q24h; 5 q12h) |
| atazanavir | 6 |
| lopinavir | 1 |
| Characteristics . | Total population (n = 32) . |
|---|---|
| Age, years, median (IQR) | 45 (41–50) |
| Male sex (%) | 57.6 |
| Subtype B (%) | 19.4 |
| CRF02_AG (%) | 53.1 |
| CD4 cell count at VF, cells/mm3, median (IQR) | 243 (103–390) |
| Nadir CD4 cell count, cells/mm3, median (IQR) | 220 (99–319) |
| Plasma HIV viral load at D0, log10 copies/mL, median (IQR) | 5.3 (5–5.5) |
| Plasma HIV viral load at VF, log10 copies/mL, median (IQR) | 2.2 (2–2.7) |
| Time to treatment failure, days, median (IQR) | 495 (366–735) |
| Treatments, number of patients | |
| 2 NRTIs+PI/r | 31 |
| tenofovir/emtricitabine+PI/r | 27 |
| 1 INSTI+PI/r | 1 |
| Protease inhibitors, number of patients | |
| darunavir | 25 (20 q24h; 5 q12h) |
| atazanavir | 6 |
| lopinavir | 1 |
D0, day 0 (baseline); INSTI, integrase inhibitor; VF, virological failure.
| Characteristics . | Total population (n = 32) . |
|---|---|
| Age, years, median (IQR) | 45 (41–50) |
| Male sex (%) | 57.6 |
| Subtype B (%) | 19.4 |
| CRF02_AG (%) | 53.1 |
| CD4 cell count at VF, cells/mm3, median (IQR) | 243 (103–390) |
| Nadir CD4 cell count, cells/mm3, median (IQR) | 220 (99–319) |
| Plasma HIV viral load at D0, log10 copies/mL, median (IQR) | 5.3 (5–5.5) |
| Plasma HIV viral load at VF, log10 copies/mL, median (IQR) | 2.2 (2–2.7) |
| Time to treatment failure, days, median (IQR) | 495 (366–735) |
| Treatments, number of patients | |
| 2 NRTIs+PI/r | 31 |
| tenofovir/emtricitabine+PI/r | 27 |
| 1 INSTI+PI/r | 1 |
| Protease inhibitors, number of patients | |
| darunavir | 25 (20 q24h; 5 q12h) |
| atazanavir | 6 |
| lopinavir | 1 |
| Characteristics . | Total population (n = 32) . |
|---|---|
| Age, years, median (IQR) | 45 (41–50) |
| Male sex (%) | 57.6 |
| Subtype B (%) | 19.4 |
| CRF02_AG (%) | 53.1 |
| CD4 cell count at VF, cells/mm3, median (IQR) | 243 (103–390) |
| Nadir CD4 cell count, cells/mm3, median (IQR) | 220 (99–319) |
| Plasma HIV viral load at D0, log10 copies/mL, median (IQR) | 5.3 (5–5.5) |
| Plasma HIV viral load at VF, log10 copies/mL, median (IQR) | 2.2 (2–2.7) |
| Time to treatment failure, days, median (IQR) | 495 (366–735) |
| Treatments, number of patients | |
| 2 NRTIs+PI/r | 31 |
| tenofovir/emtricitabine+PI/r | 27 |
| 1 INSTI+PI/r | 1 |
| Protease inhibitors, number of patients | |
| darunavir | 25 (20 q24h; 5 q12h) |
| atazanavir | 6 |
| lopinavir | 1 |
D0, day 0 (baseline); INSTI, integrase inhibitor; VF, virological failure.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
